News
Back
We advised H2B in investment in Pikralida
The LLW team had the pleasure of advising the Hard2beat fund on its investment in Pikralida.
The investment supports a key stage in the company’s growth, including:
📈 TRX-12 – preparation of the veterinary drug for U.S. registration and planned market entry in 2027/2028,
🧪 TRX-03 and TRX-06 – preparation of both clinical projects for Phase II trials,
⚖️ Regulatory & partnerships – development of regulatory strategy, obtaining MUMS and Orphan Drug Designation statuses, and further expansion of strategic partnerships.
The LLW transaction team included Jędrzej Szymczyk, LL.M., Michalina Mikołajczyk, Monika Kot.
Congratulations to the Investors – iif.vc, Hard2beat, Altamira VC and the Founders of Pikralida – Stanislaw Pikul, Joanna Lipner, PhD, MBA, Anna Krause.
